Measles and rubella virus vaccine - Takeda

Drug Profile

Measles and rubella virus vaccine - Takeda

Alternative Names: Freeze-dried live attenuated measles and rubella combined vaccine - Takeda

Latest Information Update: 07 Feb 2006

Price : $50

At a glance

  • Originator Takeda
  • Class Measles vaccines; Rubella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Rubella

Most Recent Events

  • 07 Feb 2006 First global launch for Rubella in Japan (injection)
  • 07 Feb 2006 First global launch for Measles in Japan (injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top